StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRXFree Report) in a research note issued to investors on Thursday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Down 6.8 %

Shares of NASDAQ EGRX opened at $3.73 on Thursday. The company has a market cap of $48.44 million, a price-to-earnings ratio of 3.16 and a beta of 0.45. Eagle Pharmaceuticals has a 12-month low of $3.21 and a 12-month high of $23.52. The stock’s 50 day simple moving average is $4.41 and its 200 day simple moving average is $5.25.

Institutional Trading of Eagle Pharmaceuticals

Several hedge funds have recently made changes to their positions in EGRX. Headlands Technologies LLC lifted its holdings in shares of Eagle Pharmaceuticals by 263.4% in the 3rd quarter. Headlands Technologies LLC now owns 2,326 shares of the specialty pharmaceutical company’s stock worth $37,000 after purchasing an additional 1,686 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Eagle Pharmaceuticals by 5.5% in the 3rd quarter. Acadian Asset Management LLC now owns 236,902 shares of the specialty pharmaceutical company’s stock worth $3,733,000 after purchasing an additional 12,326 shares during the last quarter. Brandes Investment Partners LP lifted its holdings in shares of Eagle Pharmaceuticals by 34.9% in the 3rd quarter. Brandes Investment Partners LP now owns 1,134,363 shares of the specialty pharmaceutical company’s stock worth $17,889,000 after purchasing an additional 293,276 shares during the last quarter. Trexquant Investment LP raised its stake in Eagle Pharmaceuticals by 26.1% during the 3rd quarter. Trexquant Investment LP now owns 67,187 shares of the specialty pharmaceutical company’s stock valued at $1,060,000 after acquiring an additional 13,910 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its stake in Eagle Pharmaceuticals by 25.0% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the specialty pharmaceutical company’s stock valued at $7,885,000 after acquiring an additional 100,000 shares in the last quarter. Institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

(Get Free Report)

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Featured Articles

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.